Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gold Nanoparticles Indicate Early Detection of Heart Attacks

By LabMedica International staff writers
Posted on 27 Jan 2015
A test strip for a heart attack biomarker is being developed as its level is several thousand times higher in patients experiencing myocardial infarctions. More...
The new strip uses microplasma technology.

Cardiac troponin I (cTn-I) is a specific marker for myocardial infarction and a new cTn-I test is based on the specific immune-chemical reactions between antigen and antibody on immunochromatographic test strips using gold nanoparticles (AuNPs).

Bioengineers at the New York University Polytechnic School of Engineering used an atmospheric-pressure non-thermal microplasma for the synthesis of aqueous gold nanoparticles (AuNPs). The microplasma-induced liquid chemistry was analyzed by monitoring the pH value and the conductivity of the liquid. A sample pad made of glass fiber was saturated with 100 mM phosphate buffered saline and the anti-cardiac troponin antibody19C7 MAb (HyTest Ltd.; Turku, Finland) was conjugated to AuNPs and sprayed onto the conjugate pad. After the addition of other antibodies, the nitrocellulose membranes were combined with the conjugate pad at the opposite end downstream of the control line. The sample pad was placed on top and in front of the conjugate pad at the site of the sample application wells.

Compared to AuNPs produced by traditional chemical methods, the surfaces of the gold nanoparticles generated by the microplasma-induced liquid chemical process attracted more antibodies, which resulted in significantly higher detection sensitivity. A positive result yields reddish bands at both the test (T) and control (C) positions, whereas a negative result yields a reddish band at position C only. The level of cTn-I is below 0.06 ng/mL in the blood of healthy people, whereas the level of cTn-I may reach 100 ng/mL to 1,300 ng/mL in patients after the onset of acute myocardial infarction (AMI) and remains high for up to four to10 days.

The authors concluded that the immune-chromatography test assays for cTn-I prepared by AuNPs generated by plasma-liquid interaction exhibit higher detection sensitivity than those prepared by chemically reduced AuNPs detection. They believe that the microplasma-assisted synthesis of AuNPs have great potential for a variety of biomedical and therapeutic applications. The study was first published online on December 11, 2014, in the journal Plasma Processes and Polymers.

Related Links:

New York University Polytechnic School of Engineering
HyTest Ltd. 



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.